Collplant biotechnologies reports 2024 second quarter financial results and provides corporate update

- recently initiated a pre-clinical trial with collplant's rhcollagen-based regenerative breast implants, printed with stratasys' origin ® 3d printer that are 200cc in volume - breast implants could address a $3.0 billion market opportunity - cash and cash equivalents balance as of june 30, 2024 was $18.9 million - conference call to be held today at 10:00 a.m. u.s. edt rehovot, israel , aug. 20, 2024 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter ended june 30, 2024, and provided a corporate update.
CLGN Ratings Summary
CLGN Quant Ranking